GRF(1-29) raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Cases of stigmatism fall into two categories: self-inflicted wounds, which may be either cases of fraud or of unconscious self-infliction, and those that are caused by emotional states ... Self-induced (through autosuggestion) itching and subsequent scratching of which the individual is unaware is likely to occur in suggestible persons if the stimulus is a mental or actual picture of the Crucifixion used during meditation and if the main motive is to receive the stigmata. The motive behind that may be unconscious conflict and a desire to escape from an intolerable situation into invalidism where one's needs are taken care of. It then becomes a case of hysterical conversion reaction. Many cases of stigmatism can be explained as fraud or unconsciously self-inflicted wounds. In his Stigmata: A Medieval Phenomenon in a Modern Age, Ted Harrison suggests that there is no single mechanism whereby the marks of stigmata were produced. Harrison found no evidence from a study of contemporary cases that the marks were supernatural in origin. He concluded, however, that marks of natural origin need not be hoaxes. Some stigmatics marked themselves in attempt to suffer with Christ as a form of piety. Others marked themselves accidentally and their marks were noted as stigmata by witnesses. Often marks of human origin produced profound and genuine religious responses. Harrison also noted that after Saint Francis of Assisi, the stigmata was "seen as a predominantly female experience" with the female-to-male ratio of stigmatics being 7 to 1.
Early researchers found that an electric or magnetic field could split radioactive emissions into three types of beams. Ernest Rutherford named the three types alpha, beta, and gamma, in increasing order of their ability to penetrate matter. Alpha decay is observed only in heavier elements of atomic number 52 (tellurium) and greater, with the exception of beryllium-8 (which decays to two alpha particles). Gamma rays are emitted from excited states of nuclei as a side effect of alpha or beta decay. Beta decay is the only type to be observed in all the elements. Lead, atomic number 82, is the heaviest element to have any isotopes stable (to the limit of measurement) to radioactive decay. Radioactive decay is seen in all isotopes of all elements of atomic number 83 (bismuth) or greater. Bismuth-209, however, is only very slightly radioactive, with a half-life greater than the age of the universe by ten orders of magnitude; radioisotopes with extremely long half-lives are considered effectively stable for practical purposes. In analyzing the nature of the decay products, it was obvious from the direction of the electromagnetic forces applied to the radiations by external magnetic and electric fields that alpha particles carried a positive charge, beta particles carried a negative charge, and gamma rays were neutral. From the magnitude of deflection, it was clear that alpha particles were much more massive than beta particles.
== Method == Classically, to perform a radioimmunoassay, a known quantity of an antigen is made radioactive, frequently by labeling it with gamma-radioactive isotopes of iodine, such as 125-I, or tritium attached to tyrosine. This radiolabeled antigen is then mixed with a known amount of antibody for that antigen, and as a result, the two specifically bind to one another. Then, a sample of serum from a patient containing an unknown quantity of that same antigen is added. This causes the unlabeled (or "cold") antigen from the serum to compete with the radiolabeled antigen ("hot") for antibody binding sites. As the concentration of "cold" antigen is increased, more of it binds to the antibody, displacing the radiolabeled variant, and reducing the ratio of antibody-bound radiolabeled antigen to free radiolabeled antigen. The bound antigens are then separated and the radioactivity of the free(unbound) antigen remaining in the supernatant is measured using a gamma counter. This value is then compared to a standardised calibration curve to work out the concentration of the unlabelled antigen in the patient serum sample. This method can be used for any biological molecule in principle and is not restricted to serum antigens, nor is it required to use the indirect method of measuring the free antigen instead of directly measuring the captured antigen.
Hans Studener (1966–1969) Kurt Holke (1969–1971) Horst Scherbaum (1971–1976) Manfred Pfeifer (1976–1978) Heinz Joerk (1978–1979) Harro Miller (1979–1985) Hans-Ulrich "Uli" Thomale (1985 – February 1990) Gunter Böhme (February 1990 – 27 May 1991) VfB Leipzig
== Overview == Ascorbate-dependent peroxidase activity was first reported in 1979, more than 150 years after the first observation of peroxidase activity in horseradish plants and almost 40 years after the discovery of the closely related cytochrome c peroxidase enzyme. Peroxidases have been classified into three types (class I, class II and class III): ascorbate peroxidases is a class I peroxidase enzyme. APXs catalyze the H2O2-dependent oxidation of ascorbate in plants, algae and certain cyanobacteria. APX has high sequence identity to cytochrome c peroxidase, which is also a class I peroxidase enzyme. Under physiological conditions, the immediate product of the reaction, the monodehydroascorbate radical, is reduced back to ascorbate by a monodehydroascorbate reductase (monodehydroascorbate reductase (NADH)) enzyme. In the absence of a reductase, two monodehydroascorbate radicals disproportionate rapidly to dehydroascorbic acid and ascorbate. APX is an integral component of the glutathione-ascorbate cycle.
Sources: en.wikipedia.org
== Impact == Following the release of The Beauty, renewed interest emerged in the original comic, The Beauty #1, published by Image Comics. The issue appeared on Key Collector Comics' "Trending 20" list and was featured by the YouTube channel ComicTom101 in its "Hot 10" rankings over multiple consecutive weeks. Secondary market activity increased, with raw copies reportedly selling for as much as $64 on eBay, while higher-grade and later printings recorded correspondingly higher prices. During the week of the series' premiere, The Beauty #1 placed No. 7 among trending comics in the United States and was reported to have reached a sale price of $199 for a CGC 9.8 copy, with a near-mint fair market value of $53 for raw copies.
One of the increasingly used methods includes the use of LA-ICP-MS. In LA-ICP-MS, a laser beam is focused on a sample surface, causing it to vaporize and form a high-temperature plasma. This plasma is then introduced into an inductively coupled plasma (ICP) source, where further ionization and excitation occur. The resulting ions are then analysed using a mass spectrometer (MS).
== Mechanism of action == The combination of lamivudine and zidovudine is composed of two nucleotide reverse transcriptase inhibitors (NRTIs). Lamivudine and zidovudine both competitively inhibit and reduce the activity of reverse transcriptase (RT) causing HIV infected cells to decrease the number of viruses in the body. Lamivudine and zidovudine act as nucleoside analogs, which are substrates for the human nucleoside kinases. The initial phosphorylation step is crucial for the drug's activity, then converted into the active 5'-triphosphate form by host kinases. The drug is then incorporated to the end of the growing chain of the viral DNA causing the chain to be terminated, where nucleotides can no longer be added to the growing viral DNA. Lamividuine and zidovudine combination therapy is believed to work synergistically together to prevent mutations in the HIV virus, which can contribute to drug resistance.
Scientists caution about potential spillover of bat sarbecovirus Khosta-2 resistant to COVID-19 vaccines and also using ACE2, suggesting it or something like it could recombine with SARS-CoV-2 as a new threat. 23 September – Astronomers report that GJ 1252b, an Earth-sized planet orbiting an M-class red dwarf, appears to have no atmosphere, which may reduce the chances of life emerging in such systems. 26 September Jupiter makes its closest approach to Earth since 1963. NASA's DART crashes into the asteroid Dimorphos in a first test of potential planetary defense. Success of path alteration is reported on 11 October. A study invalidates the common argument as is for high medication costs that research and development investments are reflected in and necessitate the treatment costs, finding no correlation for investments in drugs (for cases where transparency was sufficient) and their costs. News outlets report, based on CDC reports and health officials, that the 2022 monkeypox outbreak appears to be receding and/or passed a peak while also reporting that its elimination within the U.S. and globally is unlikely (or the outbreak being "far from finished"). 27 September – A study finds that drinking two to three cups of ground, instant, or decaffeinated coffee each day is associated with a longer lifespan and lower risk of cardiovascular disease compared with avoiding coffee.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.